ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2408

The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts

Eloise Norman1, Clare Fraser2, Mitchell Lawlor3 and Anthony Sammel4, 1Prince of Wales Hospital, Randwick, Australia, 2Save Sight Institute, The University of Sydney, Sydney, Australia, 3Sydney and Sydney Eye Hospital, Sydney, Australia, 4The Prince of Wales Hospital, Sydney, Australia

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The rate of positive temporal artery biopsies (TAB) in patients with suspected giant cell arteritis (GCA) varies widely, indicating the need for better pre-test probability evaluation. The Southend Probability Score (GCAPS) has been developed as a GCA risk stratification tool and low scores ( < 10), can exclude the diagnosis without the need for further investigation. It has not been studied in ophthalmology specific hospitals, where patients may present with a higher frequency of ophthalmic symptoms and have a greater risk of vision loss if the diagnosis is missed.

Methods: Medical records of patients who underwent temporal artery biopsy (TAB) between 2010-2020 at the quaternary Sydney and Sydney Eye Hospital (SSEH) and 2010-2017 at the tertiary Prince of Wales Hospital (POWH) were reviewed and stratified into low (score < 10), intermediate (score 10-12) and high risk (score ≥13) according to the GCAPS score.

Results: Two hundred and thirty-three patients were assessed: 160 from SSEH and 73 from POWH. All 39 patients classified as low-risk had a negative TAB result (table 1). Amongst low-risk patients, the most reported symptoms were headache (69.2%) and cranial ischemia (38.5%), which included jaw claudication, transient monocular vision disturbance and diplopia. The most frequently noted examination findings were temporal artery abnormalities (15.4%) and isolated relative-afferent pupillary defect (5.1%). None of the low-risk patients had findings consistent with arteritic anterior ischemic optic neuropathy.

Conclusion: The GCAPS reliably predicted negative biopsy results in all patients with a low-risk score. This study supports its use as a risk stratification tool in both ophthalmological and general medical settings and help to exclude the diagnosis and need for temporal artery biopsy in patients with GCAPS of less than 10.

Supporting image 1


Disclosures: E. Norman: None; C. Fraser: None; M. Lawlor: None; A. Sammel: None.

To cite this abstract in AMA style:

Norman E, Fraser C, Lawlor M, Sammel A. The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-use-of-the-southend-gca-probability-score-gcaps-in-assessing-the-risk-of-giant-cell-arteritis-in-australian-ophthalmological-and-general-medical-hospital-cohorts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-use-of-the-southend-gca-probability-score-gcaps-in-assessing-the-risk-of-giant-cell-arteritis-in-australian-ophthalmological-and-general-medical-hospital-cohorts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology